The Medical Letter®

on Drugs and Therapeutics

Volume 64 **Published online January 5, 2023**

Online Article

IN THIS ISSUE

The Medical Letter®
on Drugs and Therapeutics

Volume 64 Published online January 5, 2023

Online Article

IN THIS ISSUE

Bebtelovimab EUA Withdrawn

COVID-19 Update

Bebtelovimab EUA Withdrawn

The FDA has withdrawn its Emergency Use Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) for treatment of COVID-19. Bebtelovimab is not expected to retain activity against the Omicron variants BQ.1, BQ.1.1, and XBB, which currently cause the majority of COVID-19 cases in all regions of the US.[1-3]

The NIH currently recommends treating high-risk nonhospitalized adults with COVID-19 with either oral ritonavir-boosted nirmatrelvir *(Paxlovid)* or IV remdesivir *(Veklury)*; *Paxlovid* is preferred.[4] Both of these therapies decreased the risk of hospitalization or death significantly more than placebo in large, randomized, double-blind trials.[5,6] If these drugs are inappropriate or unavailable, use of oral molnupiravir (*Lagevrio*; available under an EUA) is recommended.[4,7]

Ritonavir-boosted nirmatrelvir, remdesivir, and molnupiravir are expected to retain activity against SARS-CoV-2 variants BQ.1, BQ.1.1, and XBB.[1] ■

1. FDA. FDA announces bebtelovimab is not currently authorized in any US region. November 30, 2022. Available at: https://bit.ly/3hoAWER. Accessed January 5, 2023.
2. CDC. COVID data tracker. Variant proportions. January 4, 2023. Available at: https://bit.ly/3Ka3HhH. Accessed January 5, 2023.
3. M Imai et al. Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB. N Engl J Med 2023; 388:89.
4. NIH. COVID-19 treatment guidelines. Therapeutic management of nonhospitalized adults with COVID-19. December 28, 2022. Available at: https://bit.ly/3w5TdLB. Accessed January 5, 2023.
5. J Hammond et al. Oral nirmatrelvir for high-risk, non-hospitalized adults with Covid-19. N Engl J Med 2022; 386:1397.
6. RL Gottlieb et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2022; 386:305.
7. NIH. COVID-19 treatment guidelines. What's new in the guidelines. December 28, 2022. Available at: https://bit.ly/3GGHGHH. Accessed January 5, 2023.

Subscription Services

Address:
The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:
Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:
To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):
1 year - $159; 2 years - $298;
3 years - $398. $65 per year for students, interns, residents, and fellows in the US and Canada.
Reprints - $45 per issue or article

Site License Inquiries:
E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk subscriptions.

Get Connected:

Copyright 2023. ISSN 0025-732X